Printer Friendly

Accentia's Analytica Group Appoints Heads of Pricing And Reimbursement and Healthcare Strategy Practices; PreMarket Services Group Prepares for Growth in Specialty Pharmacy.

NEW YORK -- The Analytica Group, Inc. ("Analytica"), a leading health services research and consulting organization and a wholly owned subsidiary of Accentia, Inc. ("Accentia"), today announced the appointment of Ed Schoonveld, MBA, as Executive Vice President and General Manager of its Pricing and Reimbursement Practice and Morris Lewis, MBA as Senior Vice President of its Healthcare Strategy Practice.

Mr. Schoonveld has more than 20 years of experience in the pharmaceutical industry in various sales, marketing and general management positions for Lederle, Wyeth-Ayerst and Eli Lilly in the United States and Europe. He has extensive expertise in pricing and reimbursement as a general manager of a European affiliate of Lederle and as head of global pricing groups at both Wyeth-Ayerst and Eli Lilly.

For the past two years, Mr. Schoonveld has been responsible for the US and Japan practice of Cambridge Pharma and has been head of that company's global pricing and reimbursement group. While at Cambridge Pharma, he advised many large drug companies on product pricing & access strategy, global pricing policy and internal organizational and process challenges.

At Eli Lilly, Mr. Schoonveld created the Global Economic Affairs Group, encompassing both strategic pricing and health outcomes. In addition, he designed and implemented new pricing and value support processes to support optimization of new molecules during development and commercialization. Mr. Schoonveld also led efforts to obtain favorable pricing and reimbursement approvals and rapid market uptake by payers worldwide.

"The Pricing and Reimbursement practice is very important to Analytica's growth strategy," said Steve Arikian, MD, President of Analytica. "Ed brings the skills, capabilities, and experience to ensure that this practice meets the growing demands of our clients," added Arikian.

Mr. Schoonveld holds an MS in engineering from the Delft University of Technology in The Netherlands and a Masters of Business Administration in Finance and International Business from UCLA.

Mr. Lewis, who will serve as practice leader for the Analytica's pharmaceutical marketing strategy consulting practice, brings almost 20 years of healthcare marketing experience.

He was previously Vice President, Consulting Services for Hastings Healthcare Group where he spearheaded consulting projects covering a wide range of products and therapeutic classes. In addition, beyond traditional marketing subjects, he provided clients with assistance in such areas as disease management, managed care marketing, and delivery of services designed to enhance the value of pharmaceutical brands.

Most recently, Mr. Lewis worked with InfoMedics, Inc., a pioneer in technology-based, one-to-one marketing solutions that provide feedback to pharmaceutical companies on the medication-taking experiences of patients taking their products.

"Morris brings specific expertise to Analytica with regard to the marketing issues associated with the successful commercialization of pharmaceutical brands," said Dr. Arikian. "This experience will be invaluable as we continue to grow and add depth to our service offerings."

"Importantly, Morris has a proven track record in consulting with large and small pharmaceutical and biotechnology companies. He has worked with many of Analytica's current clients," added Arikian.

Mr. Lewis is a graduate of the Wharton School of the University of Pennsylvania, where he received a Masters of Business Administration degree. He also received bachelor degrees in Journalism and in Accounting from Washington and Lee University.

The Analytica Group, based in New York City, works closely with pharmaceutical manufacturers, physicians, and insurers to guide optimal drug development and patient care. Since its founding in 1997, it has worked with more than 100 clients worldwide including many of the top pharmaceutical and biotech companies. Additional information can be found at its website, .

The Analytica Group is a subsidiary of Accentia, Inc., which provides comprehensive solutions in specialty pharmaceutical care by supporting pharmaceutical and biotechnology products for its clients from the point of development through product launch to the point of patient care. With over 15 years' experience in its specialty pharmacy service divisions, ACCENTIA has provided services to over 300,000 patients, most US payers and thousands of specialists. Further information is available at .
 R. Scott Jones
 (813) 864-2565
 Steve Arikian, MD
 (212) 686-8640

Make Your Opinion Count - Click Here

CONTACT: R. Scott Jones of Accentia, +1-813-864-2565, or; or Steve Arikian, MD of The Analytica Group, +1-212-686-8640, or

Web site:
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Oct 23, 2002
Previous Article:Living Tribute Honors Wright Brothers' Historical Achievement; North Carolina Hybrid First Flight Rose Bush Presented as Gift to Tournament of Roses...
Next Article:Global Imaging Systems' Second Quarter Net Income Reaches $8,496,000; Second Quarter Revenues Up Eight Percent; EPS Tops Analyst Consensus.

Related Articles
TEAMM Pharmaceuticals Announces Merger With Accentia, Inc. TEAMM to Be Acquired by Specialty Pharmaceutical Distribution and Services Company to Form...
New York Based Analytica Group to Acquire IMOR - Institute For Medical Outcome Research.
TEAMM Pharmaceuticals Announces Filing of First ANDA; TEAMM Files Its First ANDA, to Begin Introduction of Its Internally Developed Pipeline.
TEAMM Pharmaceuticals Announces Acquisition of a New Drug Delivery Technology; TEAMM Acquires Patent Pending Sustained Release Technology for...
Electronic Prescriptions and Electronic Medical Records Now Possible Using Inexpensive Digital Writing Pen.
Medicare Reform and Drop In Pharmaceutical Industry Revenue to Be Investigated By Big Pharma and Healthcare Executives at June Conference.
BioVest International Announces Expansion Of Board Of Directors; BioVest Expands Board from 7 to 11 Directors.
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected in the US and no Approved...
Accentia, Inc. Acquires a Controlling Interest in Biovest International.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters